Lantheus' blood pool agent lights up your life

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 32 No 6
Volume 32
Issue 6

Ablavar, the only commercially available blood pool MR contrast agent, lights up vasculature in this steady-state MR angiogram.

Ablavar, the only commercially available blood pool MR contrast agent, lights up vasculature in this steady-state MR angiogram. The agent entered the U.S. market early this year under the auspices of Lantheus Medical, a provider of ultrasound and nuclear medicine imaging agents. A different company, Epix Pharmaceuticals, had developed the agent, however, under the name Vasovist, and won FDA approval in December 2008 after a long struggle with American regulators.

Epix sold the U.S., Canadian, and Australian rights to market the agent to Lantheus in April 2008 for $28 million in a futile attempt to stay afloat after the company had switched its focus to the development of therapeutic drugs. Epix declared bankruptcy a year ago.

Its unique injectable MR angiography agent is approved by the FDA to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, producing high-resolution images with a single dose. Ablavar's albumin-binding properties allow the agent to persist in circulation for an extended time, illustrating vascular anomalies in both dynamic (first-pass) and steady-state imaging.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
New Research Examines Radiation Risks with CT Exposure Prior to Pregnancy
Diagnostic Imaging’s Weekly Scan: August 31 — September 6
New Echocardiography Research Suggests Emerging Marker for Cardiomyopathy Detection in Patients with Duchenne Muscular Dystrophy
© 2025 MJH Life Sciences

All rights reserved.